Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (917)	3/19/1999 9:23:00 AM
From: LLCF	Read Replies (1) \| Respond to of 3202

< "Scientists doubt speedy gene-reading machine." > This was also on the front page of the WSJ today... and FYI CTSL also thinks the stocks weakness is due to competitors press releases... ie. competition. The talk about patents holding up seems to have dried up here, anyone else worried about that? DAK

To: Rocketman who wrote (917)	3/23/1999 4:57:00 PM
From: RCMac	Read Replies (3) \| Respond to of 3202

"Who'll Sequence Human Genome First? It's Up to Phred" article in today's NY Times, focusing on the software uses in both the PKN and the MegaBace machines: nytimes.com Typically, the article mentions Celera, and "the competition" (meaning the government-financed consortium project), but INCY goes unmentioned. BTW, it's worth tracing back through the links to "related articles" -- a couple of links back there is a graphic showing the supposed positions of the three participants in the "race" to sequence the genome, not including INCY. Here is the link to that graphic: nytimes.com